BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
to the next topic, which is how are we going to figure out how not to over-treat these patients? Because you mentioned in Niagara, right, we're having patients get dervalumab up front, then chemo, then dervalumab. Now we have ambassador and checkpoint data for just adjuvant, but we also know there are probably
0
💬
0
Comments
Log in to comment.
There are no comments yet.